Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

227.78 +7.09 (+3.21%)
Delayed Quote Updated: 1:31 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ResMed Inc. Common Stock

< Previous 1 2 3 4 Next >
News headline image
Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
From Pomerantz LLP
Via GlobeNewswire
News headline image
Resmed Announces Participation in the 24th Annual Morgan Stanley Global Healthcare Conference
From Resmed, Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ResMed Inc. - RMD
From Pomerantz LLP
Via GlobeNewswire
News headline image
23XI Racing NASCAR Driver Tyler Reddick Reveals Sleep Apnea Diagnosis, Teams Up with Resmed to Help Others Recognize the Signs
Reddick, a 13-time NASCAR Cup Series winner and 2026 Daytona 500 Champion, shares how prioritizing sleep health is an important part of his recovery and performance routine 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Agreement to Sell MatrixCare Business
Sharpens Resmed’s focus on high-growth sleep and connected care markets 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
Oura Members can take action on changes in sleep or breathing patterns through educational resources from Resmed and pathways for accessing care 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed’s Global Sleep Survey Reveals Sleep is One of the Top Health Priorities, but Quality Rest Remains Out of Reach
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana
Center to Create Local Jobs and Strengthen U.S. Healthcare Supply Resilience 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
Technology uses real-world sleep data and machine learning to help people with sleep apnea start and stay on therapy 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed to Report First Quarter Fiscal 2026 Earnings on October 30, 2025
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Launches Sleep Institute to Elevate Sleep Health as a Global Priority
New global clinical insights initiative debuts at World Sleep Congress 2025 to help drive innovation in sleep health care 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds
Published in The Lancet Respiratory Medicine, research reveals sharp rise in OSA, especially among women, highlighting the need for earlier diagnosis, preventative strategies, and personalized care 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Strengthens Innovation Leadership with Dual Red Dot Design Awards and 10,000 Patents and Designs
Milestones underscore Resmed’s leadership and commitment to delivering life-changing health technology that people love 
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2025
From Resmed, Inc.
Via GlobeNewswire
News headline image
Resmed to Report Fourth Quarter Fiscal 2025 Earnings on July 31, 2025
From Resmed, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.